Abbott Laboratories (ABT) EBITDA Margin (2009 - 2026)

Abbott Laboratories has disclosed EBITDA Margin across 18 years of filings, most recently posting 13.44% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 497.0% year-over-year to 13.44%; the TTM figure through Jun 2026 stood at 15.77% (down 166.0% YoY), while the FY2025 annual figure was 18.17%, up 190.0% from the prior year.
• EBITDA Margin came in at 13.44% for Q2 2026 at Abbott Laboratories, up from 12.05% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 24.48% in Q1 2022 to a low of 12.05% in Q1 2026.
• Average EBITDA Margin over 5 years is 16.83%, with a median of 16.67% recorded in 2022.
• Year-over-year, EBITDA Margin soared 749 bps in 2022 and sank 900 bps in 2023.
• Over 5 years, EBITDA Margin stood at 12.92% in 2022, then jumped by 35 bps to 17.38% in 2023, then climbed by 0 bps to 17.41% in 2024, then gained by 13 bps to 19.64% in 2025, then tumbled by 32 bps to 13.44% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 13.44% in Q2 2026, 12.05% in Q1 2026, and 19.64% in Q4 2025.